MOLECULAR PARTNERS
Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.
MOLECULAR PARTNERS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2004-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.molecularpartners.com
Total Employee:
51+
Status:
Active
Contact:
+41 44 755 77 00
Total Funding:
188.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Aurealis Pharma
Aurealis Pharma is a biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
BioInvent
BioInvent is a research-based pharmaceutical company.
Biomics Biopharma
Biomics Biopharma is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Diatech Pharmacogenetics
Diatech Pharmacogenetics is an Italian Precision Medicine company.
Exvastat
Exvastat is an innovative, preclinical-stage pharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Halia Therapeutics
Halia is a preclinical-stage biopharmaceutical company.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Humanetics Corporation
clinical stage pharmaceutical company.
Kringle Pharma
Kringle Pharma is a biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Lipid Pharmaceuticals
Lipid Pharmaceuticals is a clinical-stage, privately held, pharmaceutical development company.
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
NuCana
NuCana is a clinical-stage biopharmaceutical company
Proveca
Proveca is a UK based pharmaceutical company.
SeQuent Scientific
SeQuent Scientific Limited is an India-based integrated pharmaceutical company.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies.
Zelluna Immunotherapy
Zelluna Immunotherapy is a privately owned Norwegian biopharmaceutical company.
Current Advisors List
Board_member
Board_observer
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Christian Zahnd CEO & Board of Directors @ Molecular Partners
CEO & Board of Directors
Thomas Schwerzmann VP Human Resources @ Molecular Partners
VP Human Resources
2014-01-01
Andreas Emmenegger CFO & Co-Entrepreneur @ Molecular Partners
CFO & Co-Entrepreneur
2007-01-01
Michael Tobias Stumpp CSO & Co-Founder @ Molecular Partners
CSO & Co-Founder
Alexander Zurcher SVP Development @ Molecular Partners
SVP Development
Julien Gander General Counsel, VP Legal @ Molecular Partners
General Counsel, VP Legal
2016-01-01
Pamela Trail Chief Scientific Officer @ Molecular Partners
Chief Scientific Officer
2018-01-01
Markus Werner VP Partnering @ Molecular Partners
VP Partnering
2018-01-01
Alexander Zurcher SVP Development @ Molecular Partners
SVP Development
Thomas Schneckenburger VP Financing, IR, Communications @ Molecular Partners
VP Financing, IR, Communications
2018-01-01
Founder
Stock Details
Investors List
Novartis
Novartis investment in Post-IPO Equity - Molecular Partners
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Post-IPO Equity - Molecular Partners
BVF Partners
BVF Partners investment in Post-IPO Equity - Molecular Partners
Camber Capital Corp
Camber Capital Corp investment in Post-IPO Equity - Molecular Partners
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Molecular Partners
Endeavour Vision
Endeavour Vision investment in Series B - Molecular Partners
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series B - Molecular Partners
Index Ventures
Index Ventures investment in Series B - Molecular Partners
BB Biotech Ventures
BB Biotech Ventures investment in Series B - Molecular Partners
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Series B - Molecular Partners
Official Site Inspections
http://www.molecularpartners.com Semrush global rank: 768.67 K Semrush visits lastest month: 51.76 K
- Host name: apollo-18524850-129.titandc.io
- IP address: 185.248.50.129
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "Molecular Partners"
PIONEERING DARPin THERAPEUTICS - Molecular Partners
Molecular Partners Presents Clinical Data Update from Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024See details»
Molecular Partners - Wikipedia
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has tw…See details»
Molecular Partners - Crunchbase Company Profile & Funding
Contact Email info@molecularpartners.com Phone Number +41 44 755 77 00 Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and …See details»
Molecular Partners - LinkedIn
Molecular Partners | 10,844 followers on LinkedIn. Pioneering DARPin Therapeutics for Patients | Molecular Partners AG is a clinical-stage biotech company pioneering the design and …See details»
At a Glance: Key Milestones, Group Profile & Contents - Molecular …
Overview on the highlights in terms of Leadership & Governance of our organization. Oncology AML candidate MP0533 is approaching Phase 1 initiation MP0533, Molecular Partners’ novel …See details»
Molecular Partners | LinkedIn
Molecular Partners | 10.920 Follower:innen auf LinkedIn. Pioneering DARPin Therapeutics for Patients | Molecular Partners AG is a clinical-stage biotech company pioneering the design …See details»
Molecular Partners Reports Corporate Highlights From Q4 2022 …
ESG strategy within the organization, Molecular Partners has created an ESG Circle of key internal stakeholders to ensure continued progress is made across key priorities. Elsewhere, …See details»
Molecular Partners and Orano Med expand partnership to develop …
2 days ago seth.lewis@molecularpartners.com Tel: +1 781 420 2361. Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland …See details»
Molecular Partners AG - Swiss Biotech
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics, a novel class …See details»
Molecular Partners - Craft
Oct 29, 2024 Molecular Partners has 5 employees across 3 locations and CHF7.04 m in annual revenue in FY 2023. See insights on Molecular Partners including office locations, …See details»
Contact Us - Molecular Partners
General inquiries info@molecularpartners.com Media contacts Swiss Media: Laura Jeanbart, Ph.D. Laura.Jeanbart@molecularpartners.com Tel: +41 44 755 77 00 International Media: …See details»
Careers - Molecular Partners
Fostering a culture of diversity and inclusion is key element of our recruitment process. Our team is comprised of individuals who are committed to creating and maintaining a sustainable …See details»
Molecular Partners - Overview, News & Similar companies
Apr 29, 2024 Who is Molecular Partners. Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed …See details»
Molecular Partners and Orano Med expand partnership to
2 days ago laura.jeanbart@molecularpartners.com Tel: +41 44 575 19 35. Orano Med Sophie Letournel Strategy, governance, and communication director sophie.letournel@orano.group …See details»
Molecular Partners Outlines Clinical Expansion Plans and …
2 days ago For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs. For further details, please contact: Seth Lewis, SVP Investor …See details»
Partnering - Molecular Partners
In January 2024, we entered into a co-development agreement with Orano Med, a pioneer in targeted alpha therapy, to develop novel Radio-DARPin Therapies (RDTs) that use Orano …See details»
Molecular Partners Outlines Clinical Expansion Plans and
1 day ago seth.lewis@molecularpartners.com Tel: +1 781 420 2361. Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland …See details»
Molecular Partners Announces Collaboration with Novartis to …
Dec 14, 2021 For further details, please contact: Seth Lewis seth.lewis@molecularpartners.com Tel: +1 781 420 2361 Shai Biran, Ph.D. shai.biran@molecularpartners.com Tel: +1 978 254 …See details»
Molecular Partners and Orano Med expand ... - MarketScreener.com
1 day ago New agreement enables both companies to fuel a broad and innovative pipeline of 212 Pb-Radio-DARPin candidates, bringing the total number of programs up to ten; Expanded …See details»
Molecular Partners Provides Updates at 41st Annual JPM …
Jan 8, 2023 www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs. For further details, please contact: Seth Lewis, SVP Investor Relations …See details»